Effects of gastric inhibitory polypeptide (GIP) and related analogues on glucagon release at normo- and hyperglycaemia in Wistar rats and isolated islets (Q28573769)

From Wikidata

Jump to navigation Jump to search

scientific journal article

Language	Label	Description	Also known as
English	Effects of gastric inhibitory polypeptide (GIP) and related analogues on glucagon release at normo- and hyperglycaemia in Wistar rats and isolated islets	scientific journal article

Statements

scholarly article

1 reference

31 January 2017

Effects of gastric inhibitory polypeptide (GIP) and related analogues on glucagon release at normo- and hyperglycaemia in Wistar rats and isolated islets (English)

1 reference

31 January 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Roslyn S. Cassidy

1

1 reference

31 January 2017

Nigel Irwin

2

1 reference

31 January 2017

Peter R. Flatt

3

1 reference

31 January 2017

publication date

1 February 2008

1 reference

31 January 2017

Biological Chemistry

1 reference

31 January 2017

389

1 reference

31 January 2017

2

1 reference

31 January 2017

189–193

1 reference

31 January 2017

The entero-insular axis in type 2 diabetes--incretins as therapeutic agents

1 reference

https://api.crossref.org/works/10.1515%2FBC.2008.019

21 January 2018

Circulation and degradation of GIP and GLP-1.

1 reference

https://api.crossref.org/works/10.1515%2FBC.2008.019

21 January 2018

Stimulation of glucagon secretion by gastric inhibitory polypeptide in patients with hepatic cirrhosis and hyperglucagonemia

1 reference

https://api.crossref.org/works/10.1515%2FBC.2008.019

21 January 2018

Characterization of the cellular and metabolic effects of a novel enzyme-resistant antagonist of glucose-dependent insulinotropic polypeptide

1 reference

https://api.crossref.org/works/10.1515%2FBC.2008.019

21 January 2018

Glucose-dependent insulinotropic polypeptide (GIP): anti-diabetic and anti-obesity potential?

1 reference

https://api.crossref.org/works/10.1515%2FBC.2008.019

21 January 2018

Chemical gastric inhibitory polypeptide receptor antagonism protects against obesity, insulin resistance, glucose intolerance and associated disturbances in mice fed high-fat and cafeteria diets.

1 reference

https://api.crossref.org/works/10.1515%2FBC.2008.019

21 January 2018

Structurally modified analogues of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) as future antidiabetic agents

1 reference

https://api.crossref.org/works/10.1515%2FBC.2008.019

21 January 2018

A novel, long-acting agonist of glucose-dependent insulinotropic polypeptide suitable for once-daily administration in type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1515%2FBC.2008.019

21 January 2018

Evaluation of the antidiabetic activity of DPP IV resistant N-terminally modified versus mid-chain acylated analogues of glucose-dependent insulinotropic polypeptide.

1 reference

https://api.crossref.org/works/10.1515%2FBC.2008.019

21 January 2018

Early administration of the glucose-dependent insulinotropic polypeptide receptor antagonist (Pro3)GIP prevents the development of diabetes and related metabolic abnormalities associated with genetically inherited obesity in ob/ob mice.

1 reference

https://api.crossref.org/works/10.1515%2FBC.2008.019

21 January 2018

The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects

1 reference

https://api.crossref.org/works/10.1515%2FBC.2008.019

21 January 2018

Small-molecule agonists for the glucagon-like peptide 1 receptor

1 reference

https://api.crossref.org/works/10.1515%2FBC.2008.019

21 January 2018

Reduced insulinotropic effect of gastric inhibitory polypeptide in first-degree relatives of patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1515%2FBC.2008.019

21 January 2018

Similar insulin secretory response to a gastric inhibitory polypeptide bolus injection at euglycemia in first-degree relatives of patients with type 2 diabetes and control subjects

1 reference

https://api.crossref.org/works/10.1515%2FBC.2008.019

21 January 2018

Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia

1 reference

https://api.crossref.org/works/10.1515%2FBC.2008.019

21 January 2018

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1515%2FBC.2008.019

21 January 2018

Improved stability, insulin-releasing activity and antidiabetic potential of two novel N-terminal analogues of gastric inhibitory polypeptide: N-acetyl-GIP and pGlu-GIP.

1 reference

https://api.crossref.org/works/10.1515%2FBC.2008.019

21 January 2018

Effect of truncated glucagon-like peptide-1 [proglucagon-(78-107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach.

1 reference

https://api.crossref.org/works/10.1515%2FBC.2008.019

21 January 2018

Suppression of glucagon secretion is lower after oral glucose administration than during intravenous glucose administration in human subjects

1 reference

https://api.crossref.org/works/10.1515%2FBC.2008.019

21 January 2018

Identifiers

10.1515/BC.2008.019

1 reference

31 January 2017

1 reference

31 January 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28573769&oldid=2009024088"